Elan's Tysabri wins one, loses one at the CHMP
This article was originally published in Scrip
Executive Summary
Elan has withdrawn one application but succeeded with another to extend the use of Tysabri (natalizumab) in multiple sclerosis, according to the European Medicines Agency's Committee for Medicinal Products for Human Use. Other products to win the okay for an expanded use include Novartis' Glivec (imatinib) and eye drug Lucentis (ranibizumab), and Pfizer's Prevnar 13